HLVX

Insider Trades

Name	Value	Action	Price	Current Price
Maltbie ShaneChief Financial Officer $7.7k4.3k shares SellFeb 11, 2025 $1.76 --
Maltbie ShaneChief Financial Officer $7.5k3.9k shares SellFeb 4, 2025 $1.89 --
Hershberg RobertDirector, Officer: See Remarks $21k11.9k shares SellFeb 11, 2025 $1.76 --
Hershberg RobertDirector, Officer: See Remarks $28k14.6k shares SellFeb 4, 2025 $1.89 --

Trade HLVX

About HilleVax, Inc.

HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.

CEO: Robert M. Hershberg
IPO Date: Apr 29, 2022

Market Data

Open: $2.09
High: $2.09
Low: $2.09
Volume: 2.8M
Avg Volume: 718.7K
52W High: $2.17
52W Low: $1.34

Valuation

Market Cap: $105M
Enterprise Value: $70M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-109M
Revenue: $0
Net Income: $-147M
Cash: $154M
Debt: $25M

Events

EarningsNov 6

EPS est. -0.15 · actual -0.52